1. Local Control For High-Grade Nonrhabdomyosarcoma Soft Tissue Sarcoma Assigned to Radiation Therapy on ARST0332: A Report From the Childrens Oncology Group
- Author
-
Million, Lynn, Hayes-Jordan, Andrea, Chi, Yueh-Yun, Donaldson, Sarah S, Wolden, Suzanne, Morris, Carol, Terezakis, Stephanie, Laurie, Fran, Morano, Karen, Fitzgerald, TJ, Yock, Torunn I, Rodeberg, David A, Anderson, James R, Speights, Rose Anne, Black, Jennifer O, Coffin, Cheryl, McCarville, Mary Beth, Kao, Simon C, Hawkins, Douglas S, Spunt, Sheri L, and Randall, R Lor
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Rare Diseases ,Clinical Research ,Patient Safety ,Pediatric ,Clinical Trials and Supportive Activities ,Pediatric Cancer ,Cancer ,6.5 Radiotherapy and other non-invasive therapies ,Evaluation of treatments and therapeutic interventions ,Adolescent ,Child ,Child ,Preschool ,Female ,Humans ,Male ,Neoplasm Grading ,Research Design ,Soft Tissue Neoplasms ,Young Adult ,Other Physical Sciences ,Oncology & Carcinogenesis ,Oncology and carcinogenesis ,Theoretical and computational chemistry ,Medical and biological physics - Abstract
PurposeThe ARST0332 trial for pediatric and young adults with nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) used risk-based treatment including primary resection with lower-than-standard radiation doses to optimize local control (LC) while minimizing long-term toxicity in those requiring radiation therapy (RT). RT for high-grade NRSTS was based on extent of resection (R0: negative margins, R1: microscopic margins, R2/U: gross disease/unresectable); those with >5 cm tumors received chemotherapy (CT; ifosfamide/doxorubicin). This analysis evaluates LC for patients assigned to RT and prognostic factors associated with local recurrence (LR).Methods and materialsPatients aged 5 cm tumor (arm C); or neoadjuvant RT (45 Gy)/CT plus delayed surgery, CT, and postoperative boost to 10.8 Gy R0
- Published
- 2021